Literature DB >> 33085050

COS-7 cells are a cellular model to monitor polyomavirus JC miR-J1-5p expression.

Simone Agostini1, Roberta Mancuso2, Andrea Saul Costa2, Franca Rosa Guerini2, Mario Clerici2,3.   

Abstract

Polyomavirus JC (JCPyV) is a ubiquitous human neurotropic virus that can cause progressive multifocal leukoencephalopathy (PML), sometimes as a consequence of drug treatment for disabling diseases, including Multiple Sclerosis. JCPyV expresses microRNAs (miRNAs), and in particular miR-J1-5p, but at now we have limited knowledge regarding this aspect. In the present study the expression of JCPyV miR-J1-5p was measured in infected COS-7, to verify if and when this miRNA is expressed in a cell model of JCPyV-MAD-4 strain infection. Results showed that miR-J1-5p expression was relatively constant inside the cells from 11 days to 35 days after infection (mean: 4.13 × 105 copies/μg), and became measurable in supernatants 18 days after infection (mean: 7.20 × 104 copies/μl). miR-J1-5p expression in supernatants peaked (3.76 × 105 copies/μl) 25 days after infection and started to decrease 32 days after infection (7.20 × 104 copies/μl). These data show that COS-7 cells, already used as model for JCPyV replication cycle, can be also utilized to study JCPyV miRNAs expression, potentially opening new research avenues for diseases in which current therapeutic approaches could result in severe adverse effects (e.g. Natalizumab-associated JCPyV reactivation in Multiple Sclerosis patients). In these situations monitoring of miR-J1-5p may shed light on the mechanisms of virus reactivation and may help the clarification of the mechanisms responsible for such severe side effects.

Entities:  

Keywords:  COS-7; JCPyV; Multiple sclerosis; Rehabilitation; ddPCR

Mesh:

Substances:

Year:  2020        PMID: 33085050     DOI: 10.1007/s11033-020-05862-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  1 in total

Review 1.  John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy.

Authors:  Valeria Pietropaolo; Carla Prezioso; Francesca Bagnato; Guido Antonelli
Journal:  New Microbiol       Date:  2018-04-05       Impact factor: 2.479

  1 in total
  2 in total

1.  JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients.

Authors:  Simone Agostini; Roberta Mancuso; Andrea Saul Costa; Domenico Caputo; Mario Clerici
Journal:  Viruses       Date:  2021-03-12       Impact factor: 5.048

2.  The MAPK/ERK Pathway and the Role of DUSP1 in JCPyV Infection of Primary Astrocytes.

Authors:  Michael P Wilczek; Francesca J Armstrong; Remi P Geohegan; Colleen L Mayberry; Jeanne K DuShane; Benjamin L King; Melissa S Maginnis
Journal:  Viruses       Date:  2021-09-14       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.